Unichem Laboratories Ltd (UNICHEMLAB)
🎯 Key Takeaways
- Unichem Laboratories is in a mature phase with stable governance and consistent promoter holding, showing no signs of active expansion or distress. The company has completed its FY2026 financial cycle with board continuity and auditor ratification, but profitability remains volatile due to exceptional items and rising operational costs despite modest revenue growth.
- Revenue grew 10% QoQ to ₹633 in Q1FY27.
- ⚠️ Profitability remains vulnerable to exceptional items and cost volatility, as seen in the sharp NP swing despite revenue growth.
- Market Cap
- ₹3,781
- P/E Ratio
- 12.4
- P/B Ratio
- 1.39
- ROE
- 11.2%
- ROCE
- 12.0%
- Debt/Equity
- 0.17
- Promoter
- 70.2%
📖 The Story
Unichem Laboratories is in a mature phase with stable governance and consistent promoter holding, showing no signs of active expansion or distress. The company has completed its FY2026 financial cycle with board continuity and auditor ratification, but profitability remains volatile due to exceptional items and rising operational costs despite modest revenue growth.
📰 What's Happening
The company concluded its 63rd AGM on August 11, 2026, where all resolutions were passed, including adoption of audited FY2026 financials and re-appointment of Managing Director Pabitrakumar Bhattacharyya. The Board also approved unaudited Q1 FY2026 results on August 11, 2026, showing revenue growth to ₹648.23 crores from ₹598.59 crores, but a sharp decline in profit after tax to ₹41.47 crores from ₹10.91 crores, driven by a ₹12.36 crore expense and a ₹201.86 crore gain from exceptional items. Earlier, on July 14, 2026, promoters confirmed no encumrances on equity holdings, reinforcing governance stability ahead of potential strategic scrutiny.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 579 | 521 | 575 | 633 |
| Operating Profit | 35 | 14 | 17 | 40 |
| OPM % | 6.0% | 2.6% | 3.0% | 6.3% |
| Net Profit | -12 | 264 | 11 | 41 |
| EPS | ₹-1.69 | ₹37.54 | ₹1.55 | ₹5.89 |
Revenue has shown sequential improvement from ₹521 crores in Dec 2025 to ₹579 crores in Sep 2025 and ₹575 crores in Mar 2026, but profitability has been inconsistent, with NP swinging from a high of ₹264 crores in Dec 2025 to a loss of ₹12 crores in Sep 2025, followed by a partial recovery to ₹41 crores in Jun 2026. Operating profit margins improved to 6.3% in Jun 2026 from 2.6% in Dec 2025, indicating some operational stabilization, but the volatility in net profit reflects non-recurring impacts and cost pressures not fully offset by revenue gains.
🔮 Management Outlook & What's Next
No forward guidance was provided in the latest AGM or board meeting filings regarding future revenue, margin, or capital allocation expectations. Management has not articulated a strategic roadmap beyond governance continuity and compliance, leaving investor expectations unclear on growth drivers or performance targets for FY2027.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 14 | 14 | 14 | 14 |
| Reserves | 2,437 | 2,387 | 2,703 | 2,421 |
| Borrowings | 460 | 300 | 469 | 502 |
| Total Liabilities | 3,569 | 3,311 | 3,737 | 3,556 |
| Fixed Assets | 1,279 | 1,151 | 1,213 | 1,230 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 3,569 | 3,311 | 3,737 | 3,556 |
The balance sheet shows stable equity of ₹14 crores and reserves growing from ₹2,421 crores to ₹2,703 crores between March 2026 and March 2026, while borrowings remained flat at ₹469 crores. Total assets increased to ₹3,737 crores, suggesting asset base expansion without significant leverage increase. This indicates conservative capital structure management and reinvestment of earnings into reserves rather than debt-funded growth.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +4 |
| Investing | +192 |
| Financing | +2 |
| Net Cash Flow | +198 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 70.2% | 70.2% | 70.2% | 70.2% |
| FII | 1.0% | 1.0% | 1.0% | 0.9% |
| DII | 10.7% | 10.7% | 10.6% | 10.5% |
| Public | 15.3% | 15.2% | 15.2% | 15.6% |
| # Shareholders | 23,577 | 23,267 | 23,386 | 25,347 |
Promoter holding remains steady at 70.22% across all quarters, with no signs of dilution or encumbrance, while institutional interest has slightly declined — FII shareholding fell from 1% to 0.91% and DII from 10.74% to 10.46% over the last four quarters. The growing number of shareholders (25,347 in Q1FY27) suggests retail participation is rising, but institutional engagement remains limited.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Profitability remains vulnerable to exceptional items and cost volatility, as seen in the sharp NP swing despite revenue growth. 2. Lack of forward guidance from management creates uncertainty on future performance. 3. Operating margins, while improving recently, are still below historical peaks and may face pressure from input costs or pricing competition in the domestic pharmaceutical market.
📋 Recent Filings
- 🔴 Announcement2026-09-26Unichem Laboratories announced that the USFDA inspected its Goa formulation facility from September 21-26, 2026, issuing five procedural observations …
- Announcement2026-09-24Unichem Laboratories announced that its trading window will close on October 1, 2026, for insiders and their relatives, remaining shut for 48 hours af…
- 🔴 Announcement2026-09-19Unichem Laboratories disclosed on September 19, 2026, that it received an Order-in-Appeal from the Commissioner (Appeals) in Thane regarding alleged G…
- 🟡 Board Meeting2026-09-11Unichem Laboratories extended the exercise periods for 75% of vested employee stock options under its 2018 scheme, pushing expiry from September 30, 2…
- 🟡 Board Meeting2026-08-12Unichem Laboratories held its 63rd AGM on 11 August 2026 via video conference, where all five resolutions were passed with requisite majority. The res…
- 🟡 Board Meeting2026-08-11Unichem Laboratories held its 63rd Annual General Meeting on 11 August 2026 via video conference, adopting audited standalone and consolidated financi…
- 🟡 Board Meeting2026-08-11Unichem Laboratories announced the Board approved its unaudited consolidated and standalone financial results for Q1 FY2026 ending June 30, 2026, cove…
- Announcement2026-07-29Unichem Laboratories disclosed that the Additional Commissioner of CGST (Appeals) in Dehradun partially allowed its appeal regarding a disputed GST cr…
- 🟡 Board Meeting2026-07-14Promoters of Unichem Laboratories declared no encumrances on their equity holdings as of March 31, 2026, confirming compliance with SEBI takeover norm…
- Announcement2026-07-10Unichem Laboratories clarified that a recent surge in its share price was purely market-driven with no undisclosed material information, reaffirming c…
🧠 Analyst's Read
Unichem Laboratories exhibits governance stability and promoter confidence, but its financial trajectory is hampered by inconsistent profitability and absence of strategic clarity. Investors should monitor upcoming earnings calls and management commentary for signs of margin improvement or capital allocation shifts, as current trends suggest limited near-term upside without clearer execution direction.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when UNICHEMLAB files new disclosures
Track UNICHEMLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track UNICHEMLAB — FreeFree account · 2 AI queries/day